Scandinavian results from three countries show effectiveness of Transpara - RAD Magazine

The Scandinavian leaders of AI in breast imaging presented their research at the ScreenPoint symposium at EUSOBI 2022 in Malmo, Sweden. Dr Kristina Lang presented the MASAI trial, the first prospective randomized controlled trial on the use of AI in breast screening as an alternative for double reading. Based on her previous retrospective studies, she is convinced that AI could lead to a more efficient and more effective screening programme. In the MASAI trial at Unilabs/Skane University Hospital Malmo, women are randomly assigned to a control arm where exams are double read as usual, or to the AI-based intervention arm: Transpara triages screening exams based on risk for malignancy and assigns 90% of all screening cases to single reading, and 10% to double reading. In addition, the top 1% most suspicious cases are automatically recalled.